Back to search

Article

Multi-Platform Comparison of Plasma Phosphorylated Tau Assays: Analytical and Workflow Factors Drive Clinical Implementation Decisions

2026-05-06

Abstract excerpt

Multiple plasma phosphorylated tau assays are now commercially available for detection of Alzheimer’s disease (AD) pathology, yet clinical laboratories lack a comprehensive comparative evaluation to guide implementation decisions. Diagnostic accuracy and analytical performance were assessed in a cohort of 273 participants with paired EDTA plasma and CSF specimens. CSF AD core biomarkers were used as the reference...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
76be66b5-f52d-57e1-93f9-72c68247044b
DOI
10.64898/2026.05.04.26352262
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Multi-Platform Comparison of Plasma Phosphorylated Tau Assays: Analytical and Workflow Factors Drive Clinical Implementation DecisionsDOI 10.64898/2026.05.04.26352262
The Alzheimers Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin studySemantic proximity
A Comprehensive Head-to-Head Comparison of Key Plasma Phosphorylated Tau 217 Biomarker TestsSemantic proximity
Analytical and Clinical Validation of a High Accuracy Fully Automated Digital Immunoassay for Plasma Phospho-Tau 217 for Clinical Use in Detecting Amyloid PathologySemantic proximity
Pittsburgh plasma p-tau217: classification accuracies for autosomal dominant and sporadic Alzheimer’s disease in the communitySemantic proximity
Development and clinical validation of blood-based multibiomarker models for the evaluation of brain amyloid pathologySemantic proximity
Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s diseaseSemantic proximity
Multi-analyte proteomic analysis identifies blood-based neuroinflammation, cerebrovascular and synaptic biomarkers in preclinical Alzheimer’s diseaseSemantic proximity
Robustness of plasma p-Tau217 diagnostic thresholds for Alzheimer’s disease across various clinical populations and laboratory environmentsSemantic proximity
Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.Semantic proximity
Plasma vs. serum: which is better for proteomic blood biomarker analysis? Evaluation of the novel NULISA platformSemantic proximity
Association of Plasma Phosphorylated Tau 217 With Clinical Deterioration Across Alzheimer Disease StagesSemantic proximity
Promising clinical tools for specific Alzheimer disease diagnosis from plasma pTau217 and ApoE genotype in a cognitive disorder unitSemantic proximity
Select a neighboring publication to make it the new centre.